Patients with MASLD displayed higher body mass index (BMI) and insulin resistance, some features of the metabolic syndrome (lower HDL‐C and higher TG), together with increased hepatic necro‐inflammatory markers (AST/ALT). This evidence concerns the gene GPT and Insulin resistance.